Simultaneous reduction in the turnover rates of septal gamma-aminobutyric acid and hippocampal acetylcholine following administration of nabilone.
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000932:Antiemetics / Q000494:pharmacology; D002540:Cerebral Cortex / Q000378:metabolism; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D006624:Hippocampus / Q000378:metabolism*; D007395:Interneurons / Q000378:metabolism; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000187:drug effects; D011963:Receptors, GABA-A; D017981:Receptors, Neurotransmitter / Q000187:drug effects; D012686:Septal Nuclei / Q000378:metabolism*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D014151:Anti-Anxiety Agents; D000932:Antiemetics; D011956:Receptors, Cell Surface; D011963:Receptors, GABA-A; D017981:Receptors, Neurotransmitter; C011941:nabilone; D005680:gamma-Aminobutyric Acid; D013759:Dronabinol; D000109:Acetylcholine